AstraZeneca Sees 2026 Sales and Profit Growth as It Builds Pipeline and Expands in U.S. and China
AstraZeneca said it expects mid-to-high single-digit revenue growth and low double-digit core profit growth in 2026, driven by demand for cancer therapies and newer drugs alongside expansion efforts in the United States and China. The Anglo-Swedish drugmaker reported modest revenue growth in the latest quarter and outlined strategic investments inc…